Mesoblast (MESO) Research & Development (2014 - 2023)
Mesoblast (MESO) posted Research & Development of $73.3 million for Q2 2023, up 1137.53% sequentially from -$7.1 million in Q1 2023, and up 20.99% YoY from $60.6 million in Q2 2022.
Mesoblast (MESO) Research & Development (2014 - 2023) Analysis & Trends
Mesoblast has reported Research & Development for 10 years, with the latest figure at $73.3 million in Q2 2023.
- Quarterly Research & Development rose 20.99% year-over-year to $73.3 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $52.8 million (up 60.96% YoY) and the FY2025 annual result came in at $34.8 million, down 12.36% from the prior year.
- Research & Development rose to $73.3 million in Q2 2023 per MESO's latest filing, from -$7.1 million in the prior quarter.
- Over five years, Research & Development peaked at $99.0 million in Q2 2021 and troughed at -$19.3 million in Q3 2020.
- A 5-year average of $9.4 million and a median of -$9.8 million in 2021 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 949.23% in 2020, down 55.61% in 2020.
- Over 5 years, Research & Development stood at -$14.2 million in 2019, then slipped by 0.59% to -$14.2 million in 2020, then advanced by 28.37% to -$10.2 million in 2021, then climbed by 24.66% to -$7.7 million in 2022, then surged by 1054.21% to $73.3 million in 2023.
- According to Business Quant data, Research & Development over the past three periods registered $73.3 million, -$7.1 million, and -$7.7 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 73.31 Mn |
| Mar 31, 2023 | -7.07 Mn |
| Dec 31, 2022 | -7.68 Mn |
| Sep 30, 2022 | -5.74 Mn |
| Jun 30, 2022 | 60.59 Mn |
| Mar 31, 2022 | -8.25 Mn |
| Dec 31, 2021 | -10.20 Mn |
| Sep 30, 2021 | -9.33 Mn |
| Jun 30, 2021 | 98.97 Mn |
| Mar 31, 2021 | -12.44 Mn |
| Dec 31, 2020 | -14.24 Mn |
| Sep 30, 2020 | -19.28 Mn |
| Jun 30, 2020 | 97.11 Mn |
| Mar 31, 2020 | -14.38 Mn |
| Dec 31, 2019 | -14.15 Mn |
| Sep 30, 2019 | -12.39 Mn |
| Jun 30, 2019 | -11.44 Mn |
| Mar 31, 2019 | -14.41 Mn |
| Dec 31, 2018 | -15.49 Mn |
| Sep 30, 2018 | -18.49 Mn |